Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ani Pharmaceuticals (ANIP) Return on Equity (2016 - 2025)

Ani Pharmaceuticals' Return on Equity history spans 15 years, with the latest figure at 0.15% for Q4 2025.

  • For Q4 2025, Return on Equity rose 25.0% year-over-year to 0.15%; the TTM value through Dec 2025 reached 0.15%, up 25.0%, while the annual FY2025 figure was 0.17%, 26.0% up from the prior year.
  • Return on Equity for Q4 2025 was 0.15% at Ani Pharmaceuticals, down from 0.19% in the prior quarter.
  • Across five years, Return on Equity topped out at 1.55% in Q3 2022 and bottomed at 15.6% in Q2 2022.
  • The 5-year median for Return on Equity is 0.06% (2024), against an average of 1.08%.
  • The largest annual shift saw Return on Equity crashed -1545bps in 2022 before it skyrocketed 1558bps in 2023.
  • A 5-year view of Return on Equity shows it stood at 0.15% in 2021, then skyrocketed by 441bps to 0.5% in 2022, then plummeted by -204bps to 0.52% in 2023, then soared by 81bps to 0.1% in 2024, then surged by 255bps to 0.15% in 2025.
  • Per Business Quant, the three most recent readings for ANIP's Return on Equity are 0.15% (Q4 2025), 0.19% (Q3 2025), and 0.28% (Q2 2025).